Mithra reports full year 2023 financial results
Mithra initiates monetization process, receives bridge loan from lenders
Mithra announces changes to its executive management
DONESTA® safety study for menopause completes treatment phase
Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of Mithra,...
Mithra updates on cash position Mithra's current cash of EUR 6.5 million is expected to cover its current cash runway through early MarchMithra is actively engaging with...
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on the...
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Important milestone for Mithra™s commitment to bring benefits of ESTELLE® to more womenPotential EMA approval in pediatric...
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessmentThe menopause phase 3 program...